bay h 4502 has been researched along with Prostatic Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brodie, AM; Clement, OO; Freeman, CM; Handratta, VD; Hartmann, RW; Njar, VC; Vasaitis, TS | 1 |
Cheng, JS; Chou, CT; Jan, CR; Kuo, CC; Kuo, DH; Liang, WZ; Shieh, P | 1 |
2 other study(ies) available for bay h 4502 and Prostatic Neoplasms
Article | Year |
---|---|
Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy.
Topics: Algorithms; Antineoplastic Agents; Azoles; Binding Sites; Enzyme Inhibitors; Humans; Hydrogen Bonding; Male; Models, Molecular; Prostatic Neoplasms; Protein Binding; Quantitative Structure-Activity Relationship; Steroid 17-alpha-Hydroxylase; Steroids | 2003 |
The mechanism of bifonazole-induced [Ca(2+)]i rises and non-Ca(2+)-triggered cell death in PC3 human prostate cancer cells.
Topics: Apoptosis; Calcium; Calcium Signaling; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Prostatic Neoplasms | 2014 |